Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surrogate End Points and Their Validation in Oncology Clinical Trials.

× No keyword cloud information.

8 in total

Review 1. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.

Authors: Md Mominur Rahman; Tapan Behl; Md Rezaul Islam; Md Noor Alam; Md Mohaimenul Islam; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Simona Gabriela Bungau
Journal: Molecules Date: 2022-06-13 Impact factor: 4.927

2. Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience.

Authors: Gennaro Galizia; Eva Lieto; Annamaria Auricchio; Francesca Cardella; Andrea Mabilia; Anna Diana; Paolo Castellano; Ferdinando De Vita; Michele Orditura
Journal: PLoS One Date: 2017-04-05 Impact factor: 3.240

Review 3. Surrogate endpoints in early prostate cancer research.

Authors: Scott Williams
Journal: Transl Androl Urol Date: 2018-06

4. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

Authors: Sandra P D'Angelo; Matthias Hunger; Andrew S Brohl; Paul Nghiem; Shailender Bhatia; Omid Hamid; Janice M Mehnert; Patrick Terheyden; Kent C Shih; Isaac Brownell; Céleste Lebbé; Karl D Lewis; Gerald P Linette; Michele Milella; Michael Schlichting; Meliessa H Hennessy; Murtuza Bharmal
Journal: Cancer Immunol Immunother Date: 2019-02-05 Impact factor: 6.968

5. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.

Authors: Jiabu Ye; Xiang Ji; Phillip A Dennis; Hesham Abdullah; Pralay Mukhopadhyay
Journal: Clin Pharmacol Ther Date: 2020-07-18 Impact factor: 6.875

6. Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis.

Authors: Zhirui Zhou; Shengxiang Ren; Lingxiao Chen; Caicun Zhou; Tao Jiang
Journal: Transl Lung Cancer Res Date: 2021-06

7. Mesenchymal Stromal Cells-Derived β2-Microglobulin Promotes Epithelial-Mesenchymal Transition of Esophageal Squamous Cell Carcinoma Cells.

Authors: Junjie Wang; Weilin Yang; Tao Wang; Xiaoyong Chen; Jiancheng Wang; Xiaoran Zhang; Chuang Cai; Beilong Zhong; Jiabin Wu; Zhenguang Chen; Andy Peng Xiang; Weijun Huang
Journal: Sci Rep Date: 2018-04-03 Impact factor: 4.379

8. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.

Authors: Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim; Kyung Won Kim
Journal: Korean J Radiol Date: 2020-04 Impact factor: 3.500

8 in total